Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | CXCR3 | P49682 | 10/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23850500 | 0.93 | CXCR3 (0.65) | KDM4ESMN1; SMN2CXCR3ALDH1A1POLB | |
| SCHEMBL19634064 | 0.86 | ALDH1A1 (0.58) | KDM4ESMN1; SMN2CXCR3ALDH1A1MEN1 | |
| SCHEMBL18753928 | 0.83 | KDM4E (0.64) | KDM4ESMN1; SMN2CXCR3ALDH1A1KMT2A | |
| SCHEMBL20971765 | 0.83 | CXCR3 (0.57) | KDM4ESMN1; SMN2CXCR3 | |
| SCHEMBL30341003 | 0.82 | KDM4E (1.00) | KDM4ESMN1; SMN2CXCR3ALDH1A1HTT | |
| SCHEMBL20238129 | 0.82 | ALDH1A1 (0.54) | KDM4ESMN1; SMN2CXCR3ALDH1A1MEN1 | |
| SCHEMBL30596611 | 0.82 | KDM4E (0.71) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29668850 | 0.82 | ALDH1A1 (0.54) | KDM4ESMN1; SMN2CXCR3ALDH1A1MEN1 | |
| SCHEMBL23775339 | 0.82 | CXCR3 (0.56) | KDM4ESMN1; SMN2CXCR3ALDH1A1KMT2A | |
| SCHEMBL10122938 | 0.82 | CXCR3 (0.56) | KDM4ESMN1; SMN2CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | KDM4E 345/4885SMN1; SMN2 843/4885CXCR3 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.